Symposium World Congress Tissue Engineering and Regenerative Medicine International Society Vienna Austria September 58 2012 Organized by TERMISAM and TERMISEU Industry Committees TERMISAM Industry Committee ID: 199572
Download Presentation The PPT/PDF document "Industry" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Industry Symposium
World CongressTissue Engineering and Regenerative Medicine International SocietyVienna, AustriaSeptember 5-8, 2012
Organized by
TERMIS-AM and TERMIS-EUIndustry CommitteesSlide2
TERMIS-AM Industry CommitteeEstablished 2009MissionSupport commercialization in Tissue Engineering/Regenerative Medicine (TE/RM)
GoalsDefine and address obstacles/hurdles to product commercializationPromote collaborations to build a viable TE/RM industryMembersKiki B. Hellman, PhD; The Hellman Group. LLC; Chair
Timothy A. Bertram, DMV, PhD; Tengion
Peter C. Johnson, MD; Avery DennisonMark Van Dyke, PhD; Wake Forest University Health SciencesBill Tawil, PhD; Baxter Biosurgery2Slide3
TERMIS-EU Industry CommitteeEstablished 2011MissionMotivate translation of academic research into commercial products, in Tissue Engineering/Regenerative Medicine (TE/RM)
Connect the scientific & clinical communities with TE/RM industriesGoalsGive answers to critical questions, paving the road of TE/RM commercial translation, by key stakeholders, from past experiences Promote
academia–industry meetings & partnerships for more effective commercial translation in TE/RM
MembersYves Bayon, PhD; Covidien – Sofradim Production; ChairSimon Ellison, MBA; NHS Blood & Transplant
John Barry, PhD; Baxter InnovationsPaul Stroemer, PhD, Reneuron
Chris Mason, PhD
; University College of London
Alain Vertes, PhD
; London Business School Sloan Fellow
3Slide4
4
Partnership, the key for successful translation of Regenerative Products
World
CongressTERMISOrganized by
TERMIS-AM and TERMIS-EU
Industry Committees
Industry SymposiumSlide5
Industry Symposium
SESSION 1:“Commercialization of Regenerative Products: The Academe/Industry
Partnership”
World CongressTissue Engineering and Regenerative Medicine International SocietyVienna, AustriaSeptember 5-8, 2012
Organized by
TERMIS-AM and TERMIS-EU
Industry CommitteesSlide6
Commercialization of Regenerative Products: The Academe/Industry PartnershipOrganizers:
TERMIS-AM & TERMIS-EU Industry CommitteesMain Goals:to learn from past academia-industry collaborative experiences in TE/RM commercial developmentto enable academia and industry to understand how best to work together and identify individual collaborations that can rapidly move forward.
6Slide7
Commercialization of Regenerative Products: The Academe/Industry Partnership7
9:05 – 9:20
Vienna/Austria - From a Strong Biomedical Tradition to a Future of Innovation and Patient Care
Ehrlich H
,
Baxter Bioscience, Austria
9:20 – 9:40
Commercialization of regenerative medicine products: the academia-industry partnership
Vertès
A
,
London Business School, Sloan Fellowship, UK
9:40 – 10:00
Commercializing regenerative medicine therapeutics and sustaining a successful business
Arshad A
,
Scientia
Advisors, USA
10:00 – 10:15
Translating academic concepts to commercial medical products: A complex academic, industrial partnership
Coury A
,
Consultant, USA
10:15 – 10:30
Successful translation of academic research using combinations of
mesenchymal
stromal
cells with pharmaceutical agents for clinical applications in regenerative medicine
Ghosh P
,
Mesoblast
Ltd, Australia